Barclays PLC Rapt Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 39,729 shares of RAPT stock, worth $48,469. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,729

Previous 39,729 -0.0%

Holding current value

$48,469

Previous $79,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$1.76 - $3.75 $51,383 - $109,481	29,195 Added 277.15%	39,729 $79,000
Q2 2024 Aug 14, 2024	SELL	$2.89 - $9.38 $237,219 - $769,938	-82,083 Reduced 88.63%	10,534 $31,000
Q1 2024 May 15, 2024	BUY	$6.87 - $26.45 $97,169 - $374,108	14,144 Added 18.02%	92,617 $831,000
Q4 2023 Feb 15, 2024	BUY	$11.28 - $25.46 $279,992 - $631,968	24,822 Added 46.27%	78,473 $1.95 Million
Q3 2023 Nov 07, 2023	SELL	$16.34 - $24.66 $176,226 - $265,958	-10,785 Reduced 16.74%	53,651 $892,000
Q2 2023 Aug 03, 2023	BUY	$16.06 - $21.61 $231,296 - $311,227	14,402 Added 28.78%	64,436 $1.21 Million
Q1 2023 May 04, 2023	SELL	$17.19 - $30.8 $509,133 - $912,234	-29,618 Reduced 37.18%	50,034 $917,000
Q4 2022 Feb 13, 2023	BUY	$16.28 - $24.6 $563,711 - $851,799	34,626 Added 76.9%	79,652 $1.58 Million
Q3 2022 Nov 03, 2022	BUY	$17.96 - $30.46 $761,396 - $1.29 Million	42,394 Added 1610.71%	45,026 $1.08 Million
Q2 2022 Aug 12, 2022	SELL	$10.26 - $23.59 $243,551 - $559,979	-23,738 Reduced 90.02%	2,632 $48,000
Q1 2022 May 16, 2022	BUY	$17.02 - $40.22 $448,817 - $1.06 Million	26,370 New	26,370 $580,000

Others Institutions Holding RAPT

# of Institutions

105

Shares Held

27.1M

Call Options Held

26.7K

Put Options Held

2.4K

View Full List

About RAPT Therapeutics, Inc.

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $36.2M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

More about RAPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account